Unity Biotechnology, Inc. (0YC0.L)
USD 0.87
(-4.92%)
USD 0.87
(-4.92%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 37.29 Million USD | -35.15% |
| 2022 | 57.5 Million USD | -11.73% |
| 2021 | 65.14 Million USD | -11.3% |
| 2020 | 73.43 Million USD | 140.67% |
| 2019 | 30.51 Million USD | 47.54% |
| 2018 | 20.68 Million USD | 84.97% |
| 2017 | 11.18 Million USD | -91.91% |
| 2016 | 138.18 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 34.87 Million USD | -6.48% |
| 2024 Q3 | 32.98 Million USD | -2.31% |
| 2024 Q2 | 33.76 Million USD | -3.17% |
| 2023 Q4 | 37.29 Million USD | 12.79% |
| 2023 Q1 | 55.62 Million USD | -3.26% |
| 2023 FY | 37.29 Million USD | -35.15% |
| 2023 Q2 | 51.6 Million USD | -7.24% |
| 2023 Q3 | 33.06 Million USD | -35.92% |
| 2022 Q1 | 61.77 Million USD | -5.17% |
| 2022 FY | 57.5 Million USD | -11.73% |
| 2022 Q4 | 57.5 Million USD | -0.56% |
| 2022 Q3 | 57.82 Million USD | 0.29% |
| 2022 Q2 | 57.66 Million USD | -6.66% |
| 2021 Q1 | 68.23 Million USD | -7.09% |
| 2021 Q4 | 65.14 Million USD | -4.14% |
| 2021 Q2 | 70.34 Million USD | 3.1% |
| 2021 FY | 65.14 Million USD | -11.3% |
| 2021 Q3 | 67.95 Million USD | -3.4% |
| 2020 FY | 73.43 Million USD | 140.67% |
| 2020 Q2 | 52.43 Million USD | -0.04% |
| 2020 Q1 | 52.45 Million USD | 71.91% |
| 2020 Q3 | 76.87 Million USD | 46.59% |
| 2020 Q4 | 73.43 Million USD | -4.46% |
| 2019 FY | 30.51 Million USD | 47.54% |
| 2019 Q4 | 30.51 Million USD | 13.18% |
| 2019 Q3 | 26.96 Million USD | -0.73% |
| 2019 Q2 | 27.16 Million USD | 91.35% |
| 2019 Q1 | 14.19 Million USD | -31.37% |
| 2018 Q1 | 242.73 Million USD | 2070.94% |
| 2018 FY | 20.68 Million USD | 84.97% |
| 2018 Q4 | 20.68 Million USD | 36.02% |
| 2018 Q3 | 15.2 Million USD | 13.58% |
| 2018 Q2 | 13.38 Million USD | -94.48% |
| 2017 FY | 11.18 Million USD | -91.91% |
| 2017 Q4 | 11.18 Million USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 FY | 138.18 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 94.024% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 70.426% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 93.963% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 85.913% |
| bluebird bio, Inc. | 424.62 Million USD | 91.218% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 45.764% |
| Imunon, Inc. | 8.53 Million USD | -337.165% |
| Editas Medicine, Inc. | 150.05 Million USD | 75.148% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.819% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 98.936% |
| Myriad Genetics, Inc. | 312.9 Million USD | 88.082% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 96.342% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 92.35% |
| Verastem, Inc. | 71.18 Million USD | 47.613% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.946% |
| Waters Corporation | 3.47 Billion USD | 98.927% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.928% |
| Biogen Inc. | 12.04 Billion USD | 99.69% |
| Nektar Therapeutics | 267.04 Million USD | 86.035% |
| Perrigo Company plc | 6.04 Billion USD | 99.383% |
| Dynavax Technologies Corporation | 375.02 Million USD | 90.056% |
| Illumina, Inc. | 4.36 Billion USD | 99.146% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -6.012% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 80.948% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 85.46% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 98.027% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 54.761% |
| Evolus, Inc. | 209.68 Million USD | 82.215% |
| Adicet Bio, Inc. | 37.12 Million USD | -0.463% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 7.294% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.475% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 94.356% |
| FibroGen, Inc. | 585.72 Million USD | 93.633% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 99.242% |
| OPKO Health, Inc. | 622.47 Million USD | 94.009% |
| Homology Medicines, Inc. | 118.53 Million USD | 68.539% |
| Geron Corporation | 146.12 Million USD | 74.48% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 99.079% |
| Exelixis, Inc. | 678.44 Million USD | 94.503% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -85.8% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -197.527% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 85.131% |
| Zoetis Inc. | 9.29 Billion USD | 99.599% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 90.613% |
| Abeona Therapeutics Inc. | 49.17 Million USD | 24.166% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.276% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 23.022% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 98.568% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 98.45% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 67.519% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 97.739% |
| Blueprint Medicines Corporation | 918.64 Million USD | 95.941% |
| Insmed Incorporated | 1.66 Billion USD | 97.756% |
| TG Therapeutics, Inc. | 169.08 Million USD | 77.945% |
| Incyte Corporation | 1.59 Billion USD | 97.658% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 96.855% |